Bionomics (BNOEF) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Bionomics (OTCMKTS:BNOEF) from a sell rating to a hold rating in a report issued on Friday.

According to Zacks, “Bionomics Limited is a biopharmaceutical company. It discovers and develops drug for the treatment of central nervous system disorders and cancer. The companys product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers’s disease; BNC101, a monoclonal antibody that targets cancer stem cells and BNC105, a novel compound to disrupt the blood vessels. It operates primarily in Australia, France and the United States. Bionomics Limited is based in Thebarton, Australia. “

Separately, ValuEngine raised shares of Bionomics from a hold rating to a buy rating in a research report on Thursday, November 1st.

OTCMKTS:BNOEF remained flat at $$0.09 during mid-day trading on Friday. 123,000 shares of the company were exchanged, compared to its average volume of 72,805. Bionomics has a 1-year low of $0.09 and a 1-year high of $0.70.

Bionomics Company Profile

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments.

See Also: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Bionomics (BNOEF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit